Review ArticlesSex-Specific Outcomes After Transcatheter Aortic Valve Replacement A Review of the LiteratureAzarbaijani, Yasameen MS; O’Callaghan, Kathryn BSE; Sanders, William E. MD, MBA; Wu, Changfu PhD; Laschinger, John MD; Marinac-Dabic, Danica MD, PhD; Strauss, David G. MD, PhD; Canos, Daniel A. MPH, PhD; Zusterzeel, Robbert MD, PhD, MPHAuthor Information From the US Food and Drug Administration, Silver Spring, MD. Supported, in part, by FDA’s Office of Women’s Health and an appointment to the Research Participation Program at the Center for Devices and Radiological Health administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and the U.S. Food and Drug Administration. Disclaimer: The mention of commercial products, their sources, or their use in connection with material reported herein is not to be construed as either an actual or implied endorsement of such products by the Department of Health and Human Services. Disclosure: The authors declare no conflict of interest. Correspondence: Robbert Zusterzeel, MD, PhD, MPH, U.S. Food and Drug Administration, 10903 New Hampshire Ave, WO 64- 2014, Silver Spring, MD 20993-0002. E-mail: email@example.com. Cardiology in Review: March/April 2018 - Volume 26 - Issue 2 - p 73-81 doi: 10.1097/CRD.0000000000000177 Buy Metrics Abstract Transcatheter aortic valve replacement (TAVR) is a safe and effective therapy for aortic valve replacement in patients ineligible for or at high risk for surgery. However, outcomes after TAVR based on an individual’s sex remain to be fully elucidated. We searched PUBMED and EMBASE using the keywords: “transcatheter aortic valve replacement,” “transcatheter aortic valve implantation,” “sex differences,” “gender,” “sex characteristics” and collected information on baseline features, procedural characteristics, and postprocedural outcomes in women. Inclusion/exclusion resulted in 23 publications. Women had less preexisting comorbidities than men. Most studies reported better survival in women (range of hazard ratio [95% CI] = 0.27 [0.09–0.84] to 0.91 [0.75–1.10]). At 30 days, women also had more vascular complications (6–20% vs 2–14%) and higher bleeding rates (10–44% vs 8–25%). Stroke rates were similar at 30 days (women, 1–7%; men, 1–5%). This literature review showed better survival in women than men after TAVR. However, women had more vascular complications and bleeding; stroke rates were similar. These findings may partly be explained by fewer baseline comorbidities in women. These results should be interpreted with caution as most measures only include unadjusted percentages. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.